HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INSILICO

50.500

-3.400-6.31%

Volume:14.77M

Turnover:746.15M

Market Cap:29.44B

PE:-11.27

High:53.350

Open:53.350

Low:49.000

Close:53.900

52wk High:80.900

52wk Low:29.980

Shares:583.00M

HK Float Shares:583.00M

Volume Ratio:1.27

T/O Rate:2.53%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-4.480

ROE:--

ROA:-1.36%

PB:6.86

PE(LYR):-11.27

PS:27.79

Loading ...

Overview Company News Filings

Movement Alert｜Insilico Medicine Rises 5.09% in Regular Trading, Strategic CNS Collaboration With Concord Pharma Worth Up to RMB 1.2 Billion in Milestones

Key Announcements from Hong Kong-Listed Companies: CITIC SEC Issues Profit Alert, Anticipating 70% Surge in First-Half Net Profit

InSilico Medicine, CMS Expand Drug Development Partnership

MT Newswires Live

Deepening Collaboration in Ai-powered R&D Acceleration: Insilico Medicine and CMS Announce Additional Collaborations in CNS Diseases

THOMSON REUTERS

Insilico Medicine Cayman Topco - Co and CMS Enter Additional Drug Development Collaboration in Central Nervous System Diseases

THOMSON REUTERS

Insilico Medicine Cayman Topco - Insilico Medicine is Eligible to Receive Milestone Payments Totaling up to Approximately Rmb1.2 Bln

THOMSON REUTERS

Movement Alert｜Insilico Medicine Rises 5.92% in Regular Trading, Positive Profit Warning Signals First-Half Turnaround to Profitability

Here's Why We're Not At All Concerned With InSilico Medicine Cayman TopCo's (HKG:3696) Cash Burn Situation

Simply Wall St.

Movement Alert｜Insilico Medicine Rises 5.89% in Regular Trading, Issues Positive Profit Warning Expecting H1 Turnaround to Profitability

INSILICO issues positive profit warning, forecasting a swing to USD33.50–39.50 million H1 2026 profit on revenue surge to over USD100 million

Bulletin Express

Insilico Projects Significant Turnaround with Profit Forecast for First Half of 2026

Insilico Medicine Cayman Topco - Expects H1 2026 Revenue of Usd102.5 Mln-usd106.5 Mln, up 272.7%-287.3% Y/Y

THOMSON REUTERS

Insilico Medicine Expects H1 2026 Net Profit of USD 33.5 Million-usd 39.5 Million

Insilico Medicine Begins Phase 3 Trial of Lung Disease Drug; Shares Up 3%

MT Newswires Live

Movement Alert｜Insilico Medicine Rises 5.16% in Regular Trading, First AI-Discovered Drug Rentosertib Enters Phase III Clinical Trial

Insilico Commences Phase 3 Trial for Rentosertib

Insilico Medicine Initiates Phase III Trial of IPF Drug Rentosertib

Insilico Initiates Phase Iii Clinical Trial for Rentosertib, Its Ai-empowered Tnik Inhibitor for Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Movement Alert｜Insilico Medicine Falls 5.11% in Regular Trading, Takeda Deal Gains Fully Priced In Amid Continued Lock-Up Selling Pressure

INSILICO expands share capital by 0.53% through option exercises and award vesting

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/03696/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"03696","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03696\",,,,,undefined,":{"symbol":"03696","market":"HK","secType":"STK","nameCN":"INSILICO","latestPrice":50.5,"timestamp":1789107174905,"preClose":53.9,"halted":0,"volume":14765210,"delay":0,"changeRate":-0.06307977736549163,"floatShares":583000000,"shares":583000000,"eps":-4.48,"marketStatus":"Trading","change":-3.4,"latestTime":"09-11 14:12:56","open":53.35,"high":53.35,"low":49,"amount":746147356,"amplitude":0.080705,"askPrice":50.5,"askSize":8000,"bidPrice":50.45,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":-4.006,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789114200000},"marketStatusCode":2,"adr":0,"listingDate":1767024000000,"exchange":"SEHK","adjPreClose":53.9,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":1.267686,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03696\",,,,,undefined,":{"symbol":"03696","floatShares":583000000,"roa":"-1.36%","roe":"--","lyrEps":-4.48,"volumeRatio":1.267686,"shares":583000000,"dividePrice":0,"high":53.35,"amplitude":0.080705,"preClose":53.9,"low":49,"week52Low":29.98,"pbRate":"6.86","psRate":"27.79","week52High":80.9,"institutionHeld":0,"latestPrice":50.5,"committee":0.272727,"eps":-4.48,"divideRate":0,"volume":14765210,"delay":0,"ttmEps":-4.006,"open":53.35,"prevYearClose":37.14,"prevWeekClose":48.76,"prevMonthClose":43.74,"prevQuarterClose":39.62,"fiveDayClose":48.76,"twentyDayClose":44.56,"sixtyDayClose":33.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03696\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"03696","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"03696","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03696\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03696\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1786032000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/03696\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"03696","date":"2026-09-10","current":-12.606091,"percent":0.432749,"low":-126.474328,"twenty":-92.953287,"median":-12.533492,"eighty":-8.808559,"high":-6.819055,"avg":-40.31383,"sd":41.480694,"marketCap":31037667229},"quantilePoints":[{"date":"2026-01-02","current":-60.518922,"twenty":-60.091977,"median":-54.070713,"eighty":-44.509914,"marketCap":20885577298},{"date":"2026-01-09","current":-75.603624,"twenty":-68.00457,"median":-60.518922,"eighty":-55.21804,"marketCap":26120865700},{"date":"2026-01-16","current":-88.730045,"twenty":-88.029114,"median":-68.708073,"eighty":-60.032461,"marketCap":30678123120},{"date":"2026-01-23","current":-103.197987,"twenty":-90.498742,"median":-83.671368,"eighty":-60.384368,"marketCap":35679909160},{"date":"2026-01-30","current":-103.586135,"twenty":-97.608242,"median":-87.528966,"eighty":-61.04227,"marketCap":35850899140},{"date":"2026-02-06","current":-102.242154,"twenty":-102.624487,"median":-88.730045,"eighty":-63.670801,"marketCap":35423424190},{"date":"2026-02-13","current":-120.862692,"twenty":-111.02361,"median":-93.674734,"eighty":-69.411577,"marketCap":41892545100},{"date":"2026-02-20","current":-120.573146,"twenty":-113.535701,"median":-95.532684,"eighty":-72.22559,"marketCap":41778551780},{"date":"2026-02-27","current":-101.790811,"twenty":-112.276672,"median":-99.165731,"eighty":-75.603624,"marketCap":35309430870},{"date":"2026-03-06","current":-91.269503,"twenty":-111.865913,"median":-96.698006,"eighty":-83.671368,"marketCap":31633146300},{"date":"2026-03-13","current":-90.695168,"twenty":-110.462075,"median":-97.855611,"eighty":-84.923636,"marketCap":31476674990},{"date":"2026-03-20","current":-90.217416,"twenty":-108.336494,"median":-95.132264,"eighty":-85.637602,"marketCap":31333988340},{"date":"2026-03-27","current":-94.081335,"twenty":-107.867915,"median":-93.382526,"eighty":-84.923636,"marketCap":32646705520},{"date":"2026-04-02","current":-11.868567,"twenty":-107.743793,"median":-93.151788,"eighty":-79.84609,"marketCap":32770014500},{"date":"2026-04-10","current":-12.877757,"twenty":-106.637664,"median":-92.691879,"eighty":-68.00457,"marketCap":35546164200},{"date":"2026-04-17","current":-12.624497,"twenty":-104.449464,"median":-91.076584,"eighty":-59.957423,"marketCap":34802041600},{"date":"2026-04-24","current":-14.676127,"twenty":-103.459526,"median":-89.747522,"eighty":-15.148699,"marketCap":40497441500},{"date":"2026-04-30","current":-13.071473,"twenty":-103.255287,"median":-88.68986,"eighty":-14.223075,"marketCap":36089946100},{"date":"2026-05-08","current":-13.340785,"twenty":-103.091175,"median":-88.574112,"eighty":-13.384736,"marketCap":36805448600},{"date":"2026-05-15","current":-10.983422,"twenty":-102.596106,"median":-86.723486,"eighty":-13.331626,"marketCap":30308685900},{"date":"2026-05-22","current":-10.451313,"twenty":-102.308283,"median":-85.637602,"eighty":-12.881328,"marketCap":28849060800},{"date":"2026-05-29","current":-8.622113,"twenty":-102.242154,"median":-83.671368,"eighty":-12.624497,"marketCap":23800475160},{"date":"2026-06-05","current":-7.875348,"twenty":-101.790811,"median":-78.255166,"eighty":-12.515704,"marketCap":21739827960},{"date":"2026-06-12","current":-7.01543,"twenty":-100.06892,"median":-65.190557,"eighty":-12.085532,"marketCap":19370083680},{"date":"2026-06-18","current":-7.947724,"twenty":-100.046598,"median":-60.518922,"eighty":-10.958896,"marketCap":21945892680},{"date":"2026-06-26","current":-7.919554,"twenty":-99.340788,"median":-54.070713,"eighty":-10.005367,"marketCap":21877204440},{"date":"2026-07-03","current":-7.743582,"twenty":-98.690073,"median":-27.191152,"eighty":-9.565807,"marketCap":21396386760},{"date":"2026-07-10","current":-8.877372,"twenty":-98.062553,"median":-14.676127,"eighty":-8.824583,"marketCap":24510253640},{"date":"2026-07-17","current":-8.953114,"twenty":-97.4013,"median":-14.167396,"eighty":-8.882012,"marketCap":24727766400},{"date":"2026-07-24","current":-9.751189,"twenty":-96.617922,"median":-13.560542,"eighty":-8.925911,"marketCap":26937238120},{"date":"2026-07-31","current":-9.466525,"twenty":-95.411086,"median":-13.340785,"eighty":-8.88656,"marketCap":26158771400},{"date":"2026-08-07","current":-9.410567,"twenty":-94.035578,"median":-13.201047,"eighty":-8.763781,"marketCap":26009946880},{"date":"2026-08-14","current":-9.225945,"twenty":-93.733176,"median":-12.895614,"eighty":-8.825762,"marketCap":25506233120},{"date":"2026-08-21","current":-8.414722,"twenty":-93.349385,"median":-12.788902,"eighty":-8.725669,"marketCap":23250969240},{"date":"2026-08-28","current":-11.42993,"twenty":-93.240519,"median":-12.603589,"eighty":-8.725669,"marketCap":26661298566},{"date":"2026-09-04","current":-12.035257,"twenty":-93.142096,"median":-12.516782,"eighty":-8.763781,"marketCap":28077860002},{"date":"2026-09-10","current":-13.302248,"twenty":-92.953287,"median":-12.533492,"eighty":-8.808559,"marketCap":31037667229}],"updateTime":1789107176121},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03696\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1182098857","title":"Movement Alert｜Insilico Medicine Rises 5.09% in Regular Trading, Strategic CNS Collaboration With Concord Pharma Worth Up to RMB 1.2 Billion in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=1182098857","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182098857?lang=en_us&edition=fundamental","pubTime":"2026-07-13 09:41","pubTimestamp":1783906863,"startTime":"0","endTime":"0","summary":"On July 13, Insilico Medicine rose 5.09% in regular trading, trading at HKD 45.94 per share, with turnover of HKD 168 million.On the news front, the company announced it has entered into a strategic...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121933478","title":"Key Announcements from Hong Kong-Listed Companies: CITIC SEC Issues Profit Alert, Anticipating 70% Surge in First-Half Net Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1121933478","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121933478?lang=en_us&edition=fundamental","pubTime":"2026-07-13 09:25","pubTimestamp":1783905910,"startTime":"0","endTime":"0","summary":"Significant corporate announcements have been released by several Hong Kong-listed companies.Xunce Technology (03317) has entered into a strategic cooperation memorandum with Lutech.51VR (06651) has...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1155","BK0028","BK4588","LU1997245094.SGD","LU0405327148.USD","LU1781817850.SGD","BK4585","06030","BK1564","LU1997245177.USD","BK0183","LU1255011170.USD","BK0276","LU1328615791.USD","LU0405327494.USD","LU1720050803.USD","BK0188","LU1064131003.USD","BK0012","LU2289578879.USD","LU2495084118.USD","LU1997244956.HKD","BK1516","600030","BK1141","LU1655091616.SGD","03696","BK1521","BK1190","BK0196","KCAI","09971","LU1794554557.SGD","LU1064130708.USD","VXUS","03833","LU2148510915.USD","03317","BK1147","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651646481","title":"InSilico Medicine, CMS Expand Drug Development Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2651646481","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651646481?lang=en_us&edition=fundamental","pubTime":"2026-07-13 09:02","pubTimestamp":1783904540,"startTime":"0","endTime":"0","summary":"InSilico Medicine  expanded its collaboration with China Medical System  to jointly develop innovative drugs for central nervous system diseases, according to a Monday filing with the Hong Kong bourse.Under the agreement, InSilico will combine its artificial intelligence drug discovery platform with CMS' research and development capabilities and therapeutic expertise to advance the programs.InSilico said it is eligible to receive milestone payments of up to 1.20 billion yuan, plus royalties based on net sales under the collaboration.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1894683348.USD","IE00BVYPNP33.GBP","SG9999015986.USD","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","BK4588","LU1894683264.USD","SG9999015978.USD","8A8.SI","BK1191","SG9999004220.SGD","LU2346227817.USD","CMS","03696","BK1593","LU2488822045.USD","LU0545039389.USD","LU2500361329.USD","LU0553294199.USD","LU1003077747.HKD","BK6079","00867","LU2637428348.USD","BK1141","LU0949170772.SGD","SG9999015952.SGD","IE00BVYPNQ40.USD","IE00BYV24P56.USD","SG9999015945.SGD","LU0661504455.SGD","LU0738911758.USD","BK4585","BK4208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651064161","title":"Deepening Collaboration in Ai-powered R&D Acceleration: Insilico Medicine and CMS Announce Additional Collaborations in CNS Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2651064161","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651064161?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:30","pubTimestamp":1783902601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUAC7RTHX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651619481","title":"Insilico Medicine Cayman Topco - Co and CMS Enter Additional Drug Development Collaboration in Central Nervous System Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2651619481","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651619481?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:00","pubTimestamp":1783900859,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43C16L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651161918","title":"Insilico Medicine Cayman Topco - Insilico Medicine is Eligible to Receive Milestone Payments Totaling up to Approximately Rmb1.2 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2651161918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651161918?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:00","pubTimestamp":1783900859,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43C16L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141701482","title":"Movement Alert｜Insilico Medicine Rises 5.92% in Regular Trading, Positive Profit Warning Signals First-Half Turnaround to Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=1141701482","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141701482?lang=en_us&edition=fundamental","pubTime":"2026-07-10 10:15","pubTimestamp":1783649722,"startTime":"0","endTime":"0","summary":"On July 10, Insilico Medicine rose 5.92% in regular trading, trading at 42.4 HKD/share with turnover of HKD 282 million, extending strong momentum following its positive profit warning issued the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901463","title":"Here's Why We're Not At All Concerned With InSilico Medicine Cayman TopCo's (HKG:3696) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901463","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650901463?lang=en_us&edition=fundamental","pubTime":"2026-07-10 08:52","pubTimestamp":1783644770,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3696/insilico-medicine-cayman-topco-shares/news/heres-why-were-not-at-all-concerned-with-insilico-medicine-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3696/insilico-medicine-cayman-topco-shares/news/heres-why-were-not-at-all-concerned-with-insilico-medicine-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182724775","title":"Movement Alert｜Insilico Medicine Rises 5.89% in Regular Trading, Issues Positive Profit Warning Expecting H1 Turnaround to Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=1182724775","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182724775?lang=en_us&edition=fundamental","pubTime":"2026-07-09 09:43","pubTimestamp":1783561385,"startTime":"0","endTime":"0","summary":"On July 9, Insilico Medicine rose 5.89% in regular trading, trading at HKD 38.78/share, with turnover of HKD 234 million. The rally was driven by the company's positive profit warning issued earlier...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159081504","title":"INSILICO issues positive profit warning, forecasting a swing to USD33.50–39.50 million H1 2026 profit on revenue surge to over USD100 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1159081504","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159081504?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:22","pubTimestamp":1783556558,"startTime":"0","endTime":"0","summary":"InSilico Medicine Cayman TopCo (INSILICO) expects a sharp turnaround for the six months ended 30 June 2026, according to a positive profit warning released on 9 July. Revenue is projected at...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198339503","title":"Insilico Projects Significant Turnaround with Profit Forecast for First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1198339503","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198339503?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:16","pubTimestamp":1783556182,"startTime":"0","endTime":"0","summary":"Insilico (HKEX: 03696) has issued a positive profit alert, forecasting a substantial financial improvement for the first half of 2026.The company anticipates reporting revenue in the range of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650914589","title":"Insilico Medicine Cayman Topco - Expects H1 2026 Revenue of Usd102.5 Mln-usd106.5 Mln, up 272.7%-287.3% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2650914589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650914589?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:01","pubTimestamp":1783555273,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nFWN43A0Z2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650914329","title":"Insilico Medicine Expects H1 2026 Net Profit of USD 33.5 Million-usd 39.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2650914329","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650914329?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:00","pubTimestamp":1783555236,"startTime":"0","endTime":"0","summary":"Insilico Medicine expects H1 2026 net profit of USD 33.5 million-USD 39.5 millionInsilico Medicine flagged a swing to profit in H1 2026, based on unaudited management accounts.Revenue expected at USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL58JJyZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649957959","title":"Insilico Medicine Begins Phase 3 Trial of Lung Disease Drug; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649957959","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649957959?lang=en_us&edition=fundamental","pubTime":"2026-07-08 12:36","pubTimestamp":1783485367,"startTime":"0","endTime":"0","summary":"Insilico Medicine  said Tuesday it has initiated a phase 3 clinical trial of rentosertib in China, according to a Wednesday filing with the Hong Kong bourse.Shares of the biotechnology company rose 3% in recent trade.The trial is designed to evaluate the efficacy and safety of the drug in treating idiopathic pulmonary fibrosis, a lung disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162276341","title":"Movement Alert｜Insilico Medicine Rises 5.16% in Regular Trading, First AI-Discovered Drug Rentosertib Enters Phase III Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1162276341","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162276341?lang=en_us&edition=fundamental","pubTime":"2026-07-08 10:35","pubTimestamp":1783478114,"startTime":"0","endTime":"0","summary":"On July 8, Insilico Medicine rose 5.16% in regular trading, trading at HK$38.02/share, with turnover of HK$185 million, reversing the prior session's decline.On the news front, the company announced...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191879696","title":"Insilico Commences Phase 3 Trial for Rentosertib","url":"https://stock-news.laohu8.com/highlight/detail?id=1191879696","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191879696?lang=en_us&edition=fundamental","pubTime":"2026-07-08 08:44","pubTimestamp":1783471462,"startTime":"0","endTime":"0","summary":"The biopharmaceutical company Insilico (03696) has announced the official initiation of a Phase 3 clinical trial for its internally developed drug candidate, Rentosertib (ISM001-055).The trial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","03696","IBBQ","BK1141","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649933569","title":"Insilico Medicine Initiates Phase III Trial of IPF Drug Rentosertib","url":"https://stock-news.laohu8.com/highlight/detail?id=2649933569","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649933569?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:44","pubTimestamp":1783431896,"startTime":"0","endTime":"0","summary":"Insilico Medicine initiates Phase III trial of IPF drug rentosertibInsilico Medicine initiated a Phase III trial of Rentosertib for idiopathic pulmonary fibrosis, its first asset to enter late-stage t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL6rDdMf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649933314","title":"Insilico Initiates Phase Iii Clinical Trial for Rentosertib, Its Ai-empowered Tnik Inhibitor for Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2649933314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649933314?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:43","pubTimestamp":1783431819,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA28TYX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147231776","title":"Movement Alert｜Insilico Medicine Falls 5.11% in Regular Trading, Takeda Deal Gains Fully Priced In Amid Continued Lock-Up Selling Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1147231776","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147231776?lang=en_us&edition=fundamental","pubTime":"2026-07-07 13:03","pubTimestamp":1783400581,"startTime":"0","endTime":"0","summary":"On July 7, Insilico Medicine fell 5.11% in regular trading, trading at HK$34.84/share, with turnover of HK$207 million. The stock has weakened for multiple consecutive sessions following the Takeda...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169879565","title":"INSILICO expands share capital by 0.53% through option exercises and award vesting","url":"https://stock-news.laohu8.com/highlight/detail?id=1169879565","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169879565?lang=en_us&edition=fundamental","pubTime":"2026-07-06 22:43","pubTimestamp":1783349022,"startTime":"0","endTime":"0","summary":"InSilico Medicine Cayman TopCo (INSILICO, HKEx: 03696) reported a 0.53% increase in its issued share capital following the allotment of 3.05 million new ordinary shares between 2 July and 6 July...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}